Skip to main content
logo
Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
68.88
-1.14 (-1.63%)
Aug 13, 2026, 4:00 PM EDT - Market closed

Tarsus Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
606.33451.36182.9517.4525.8257.03
Revenue Growth
105.17%146.71%948.62%-32.42%-54.73%-
Gross Profit
565.59420.68170.1315.8524.8654.95
Operating Income
-48.54-70.97-120.57-143.16-62.71-12.16
Net Income
-46.48-66.42-115.55-135.89-62.09-13.83
Earnings Per Share
-1.09-1.59-3.07-4.62-2.52-0.67
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
449.69417.27291.38227.44217.03171.82
Total Debt
72.7672.4471.8529.8219.430
Net Cash (Debt)
376.93344.83219.53197.62197.59171.82
Net Cash Growth
21.98%57.08%11.09%0.02%15.00%2.19%
Net Cash Per Share
8.788.255.846.738.038.36

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
74.16-12.45-83.03-117.49-49.033.75
Capital Expenditures
-18.16-9.86-1.57-1.5-0.51-0.59
Free Cash Flow
56-22.31-84.59-119-49.543.16
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
93.28%93.20%92.99%90.87%96.30%96.36%
Operating Margin
-8.00%-15.72%-65.90%-820.53%-242.92%-21.32%
Pretax Margin
-6.43%-14.26%-60.92%-778.89%-234.90%-18.49%
Profit Margin
-7.67%-14.72%-63.16%-778.89%-240.51%-24.25%
FCF Margin
9.24%-4.94%-46.24%-682.04%-191.88%5.54%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-97.48----
P/FCF Ratio
53.97----147.29
PS Ratio
4.997.7211.6139.7115.188.17